410 related articles for article (PubMed ID: 30689920)
1. The long and the short of it: the MDM4 tail so far.
Haupt S; Mejía-Hernández JO; Vijayakumaran R; Keam SP; Haupt Y
J Mol Cell Biol; 2019 Mar; 11(3):231-244. PubMed ID: 30689920
[TBL] [Abstract][Full Text] [Related]
2. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
3. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
Fan C; Wang X
Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
[TBL] [Abstract][Full Text] [Related]
4. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
[TBL] [Abstract][Full Text] [Related]
5. Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53.
Parant J; Chavez-Reyes A; Little NA; Yan W; Reinke V; Jochemsen AG; Lozano G
Nat Genet; 2001 Sep; 29(1):92-5. PubMed ID: 11528400
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of CCDC106 regulating the p53-Mdm2/MdmX signaling axis.
Zhou T; Ke Z; Ma Q; Xiang J; Gao M; Huang Y; Cheng X; Su Z
Sci Rep; 2023 Dec; 13(1):21892. PubMed ID: 38081879
[TBL] [Abstract][Full Text] [Related]
7. MDMX Recruits UbcH5c to Facilitate MDM2 E3 Ligase Activity and Subsequent p53 Degradation
Yang J; Jin A; Han J; Chen X; Zheng J; Zhang Y
Cancer Res; 2021 Feb; 81(4):898-909. PubMed ID: 33277368
[TBL] [Abstract][Full Text] [Related]
8. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.
Pant V; Xiong S; Iwakuma T; Quintás-Cardama A; Lozano G
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11995-2000. PubMed ID: 21730132
[TBL] [Abstract][Full Text] [Related]
9. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
[TBL] [Abstract][Full Text] [Related]
10. S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia.
Liu L; Fan L; Fang C; Zou ZJ; Yang S; Zhang LN; Li JY; Xu W
Cancer Sci; 2012 Dec; 103(12):2056-63. PubMed ID: 22937789
[TBL] [Abstract][Full Text] [Related]
11. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
12. CDK9 activity is critical for maintaining MDM4 overexpression in tumor cells.
Štětková M; Growková K; Fojtík P; Valčíková B; Palušová V; Verlande A; Jorda R; Kryštof V; Hejret V; Alexiou P; Rotrekl V; Uldrijan S
Cell Death Dis; 2020 Sep; 11(9):754. PubMed ID: 32934219
[TBL] [Abstract][Full Text] [Related]
13. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo.
Francoz S; Froment P; Bogaerts S; De Clercq S; Maetens M; Doumont G; Bellefroid E; Marine JC
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3232-7. PubMed ID: 16492744
[TBL] [Abstract][Full Text] [Related]
14. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
[TBL] [Abstract][Full Text] [Related]
16. Estrogen receptor alpha (ERα/ESR1) mediates the p53-independent overexpression of MDM4/MDMX and MDM2 in human breast cancer.
Swetzig WM; Wang J; Das GM
Oncotarget; 2016 Mar; 7(13):16049-69. PubMed ID: 26909605
[TBL] [Abstract][Full Text] [Related]
17. Augmented antitumor activity of 5-fluorouracil by double knockdown of MDM4 and MDM2 in colon and gastric cancer cells.
Imanishi M; Yamamoto Y; Wang X; Sugaya A; Hirose M; Endo S; Natori Y; Yamato K; Hyodo I
Cancer Sci; 2019 Feb; 110(2):639-649. PubMed ID: 30488540
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
19. MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.
Chinnam M; Xu C; Lama R; Zhang X; Cedeno CD; Wang Y; Stablewski AB; Goodrich DW; Wang X
PLoS Genet; 2022 May; 18(5):e1010171. PubMed ID: 35588102
[TBL] [Abstract][Full Text] [Related]
20. Reduced murine double minute 2 and 4 protein, but not messenger RNA, expression is associated with more severe disease in myelodysplastic syndromes and acute myeloblastic leukaemia.
Salomao N; Maslah N; Giulianelli A; Drevon L; Aguinaga L; Gu X; Cassinat B; Giraudier S; Fenaux P; Fahraeus R
Br J Haematol; 2023 Apr; 201(2):234-248. PubMed ID: 36546586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
